Stock Expert AI

InMode Ltd. (INMD)

InMode Ltd. specializes in minimally invasive aesthetic medical products utilizing radiofrequency technologies. The company offers a range of devices for various cosmetic procedures and women's health applications, both in the US and internationally.

45/100 AI Score MCap 1B Vol 730K

Company Overview

CEOMoshe Mizrahy
Employees599
HeadquartersYokne'am, IL
Founded2019

InMode Ltd. is a leader in the aesthetic medical device market, leveraging proprietary radiofrequency technology to deliver minimally invasive solutions with a high profit margin of 41.0% and a P/E ratio of 6.38, offering significant growth potential in a burgeoning industry.

Investment Thesis

InMode presents a compelling investment opportunity due to its innovative radiofrequency-based aesthetic medical devices and strong financial performance. With a high profit margin of 41.0% and a gross margin of 78.8%, the company demonstrates efficient operations and pricing power. The company's P/E ratio of 6.38 suggests it may be undervalued relative to its earnings. Growth catalysts include expanding applications of its technology, increasing adoption of minimally invasive procedures, and geographic expansion into new markets. The company's focus on proprietary technology and a diverse product portfolio provides a competitive edge. Continued innovation and strategic market penetration should drive revenue growth and enhance shareholder value. The company's strong market position and profitability make it an attractive investment for long-term growth.

Key Highlights

  • Market Cap of $1.02B reflects investor confidence in InMode's growth potential and market leadership.
  • P/E ratio of 6.38 indicates a potentially undervalued stock relative to its earnings, suggesting an attractive entry point for investors.
  • Profit Margin of 41.0% showcases InMode's efficient operations and strong pricing power within the aesthetic medical device market.
  • Gross Margin of 78.8% demonstrates the company's ability to maintain high profitability on its products and services.
  • Beta of 2.17 indicates higher volatility compared to the market, suggesting potential for higher returns but also increased risk.

Competitors

AdaptHealth Corp.AnaptysBio, Inc.Axogen Inc.CytoVac ASIntegra LifeSciences Holdings Corporation

Strengths

  • Proprietary and innovative radiofrequency technology.
  • High profit margins and strong financial performance.
  • Diverse product portfolio targeting various aesthetic procedures.
  • Established brand reputation in the aesthetic medical device market.

Weaknesses

  • High beta indicates higher volatility compared to the market.
  • Reliance on the aesthetic medical device market, which can be sensitive to economic conditions.
  • Potential competition from larger medical device companies.
  • Geographic concentration in certain markets.

Catalysts

  • Upcoming: Launch of new products incorporating advanced radiofrequency technologies.
  • Ongoing: Expansion of sales and marketing efforts in key international markets.
  • Ongoing: Increasing adoption of minimally invasive aesthetic procedures.
  • Ongoing: Strategic partnerships with leading medical professionals and institutions.

Risks

  • Potential: Intense competition from established and emerging players in the aesthetic medical device market.
  • Potential: Changes in regulatory requirements and healthcare policies could impact product approvals and market access.
  • Potential: Economic downturns could reduce demand for cosmetic procedures.
  • Ongoing: Product liability claims and recalls could damage the company's reputation and financial performance.
  • Ongoing: Dependence on key personnel and the ability to attract and retain talent.

Growth Opportunities

  • Expansion into New Geographic Markets: InMode has the opportunity to expand its presence in underserved international markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in demand for aesthetic procedures, driven by rising disposable incomes and increasing awareness of cosmetic treatments. By establishing strategic partnerships and distribution networks, InMode can tap into these markets and significantly increase its revenue. This expansion could contribute to a substantial increase in revenue within the next 3-5 years.
  • Development of New Applications for Existing Technologies: InMode can leverage its existing radiofrequency technologies to develop new applications in areas such as dermatology, gynecology, and other medical specialties. By expanding its product offerings into these adjacent markets, InMode can diversify its revenue streams and reduce its reliance on the core aesthetic market. This strategy could involve developing new devices or adapting existing ones to address specific medical needs. The timeline for this growth opportunity is estimated at 2-4 years.
  • Increased Adoption of Hands-Free Technologies: InMode's hands-free medical aesthetic products, which target skin tightening, fat reduction, and muscle stimulation, represent a significant growth opportunity. These devices offer convenience and ease of use, appealing to a broader range of practitioners and patients. By investing in marketing and education initiatives to promote the benefits of these technologies, InMode can drive increased adoption and market penetration. The market for hands-free aesthetic devices is expected to grow substantially over the next 3 years.
  • Strategic Acquisitions of Complementary Technologies: InMode can pursue strategic acquisitions of companies with complementary technologies or product lines to expand its portfolio and enhance its competitive position. This could involve acquiring companies specializing in other energy-based devices, injectables, or skincare products. By integrating these acquisitions, InMode can offer a more comprehensive suite of solutions to its customers and capture a larger share of the aesthetic market. The timeline for this growth opportunity is dependent on identifying suitable acquisition targets.
  • Focus on Women's Health Applications: InMode has a unique opportunity to expand its presence in the women's health market with its minimally invasive solutions for various conditions and procedures. By developing and marketing targeted products for women's health, InMode can address a significant unmet need and establish a strong foothold in this growing market segment. This could involve developing new devices or adapting existing ones to address specific women's health concerns. The timeline for this growth opportunity is estimated at 3-5 years.

Opportunities

  • Expansion into new geographic markets, particularly in Asia and Latin America.
  • Development of new applications for existing technologies in dermatology and gynecology.
  • Increased adoption of hands-free technologies.
  • Strategic acquisitions of complementary technologies and product lines.

Threats

  • Intense competition from existing and emerging players in the aesthetic medical device market.
  • Changes in regulatory requirements and healthcare policies.
  • Economic downturns that could reduce demand for cosmetic procedures.
  • Product liability claims and recalls.

Competitive Advantages

  • Proprietary Radiofrequency Technology: InMode's patented RFAL and SDFR technologies provide a significant competitive advantage.
  • Comprehensive Product Portfolio: A diverse range of products targeting various aesthetic procedures caters to a broad customer base.
  • Established Brand Reputation: InMode has built a strong reputation for innovation and quality in the aesthetic medical device market.
  • High Profit Margins: The company's efficient operations and pricing power contribute to high profit margins.

About

InMode Ltd., founded in 2008 and headquartered in Yokneam, Israel, is a global leader in the design, development, manufacture, and marketing of minimally invasive aesthetic medical products. The company's core technology revolves around its proprietary radiofrequency assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency (SDFR) technologies. These technologies power a diverse portfolio of products used in a wide array of aesthetic procedures, including liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. In addition to its core aesthetic offerings, InMode also provides solutions for women's health conditions and procedures. The company's product line extends to non-invasive medical aesthetic devices targeting permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, and the treatment of vascular and pigmented lesions. Furthermore, InMode offers hands-free medical aesthetic products designed for skin tightening, fat reduction, and muscle stimulation. Originally incorporated as Invasix Ltd., the company rebranded as InMode Ltd. in November 2017 to better reflect its innovative approach and expanding product offerings. InMode's products are sold both in the United States and internationally, positioning the company as a key player in the global aesthetic medical device market.

What They Do

  • Designs minimally invasive aesthetic medical products.
  • Develops radiofrequency-assisted lipolysis (RFAL) technology.
  • Manufactures medical devices for body and face contouring.
  • Markets products for ablative skin rejuvenation treatments.
  • Offers solutions for women's health conditions.
  • Provides non-invasive medical aesthetic products.
  • Creates devices for permanent hair reduction and wrinkle reduction.
  • Develops hands-free medical aesthetic products.

Business Model

  • Sells minimally invasive aesthetic medical devices to physicians and medical professionals.
  • Generates revenue through direct sales and distribution networks.
  • Offers a range of products targeting various aesthetic procedures.
  • Focuses on proprietary radiofrequency technologies for competitive advantage.

FAQ

What does InMode Ltd. do?

InMode Ltd. is a global medical device company that designs, develops, manufactures, and markets minimally invasive aesthetic medical products. The company's core technology is based on radiofrequency assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency (SDFR). These technologies are used in a variety of aesthetic procedures, including body contouring, skin tightening, and ablative skin rejuvenation. InMode sells its products to physicians, medical spas, and aesthetic clinics worldwide, offering a comprehensive portfolio of solutions for the aesthetic market.

Is INMD stock a good buy?

INMD stock presents a mixed picture. Its high profit margin of 41.0% and gross margin of 78.8% suggest strong profitability. The P/E ratio of 6.38 may indicate undervaluation. However, the high beta of 2.17 suggests significant volatility. Growth opportunities in new markets and applications exist, but competition and economic factors pose risks. Investors should weigh the potential for high returns against the increased risk before investing, considering their own risk tolerance and investment horizon.

What are the main risks for INMD?

The main risks for InMode include intense competition in the aesthetic medical device market, which could pressure pricing and market share. Changes in regulatory requirements and healthcare policies could impact product approvals and market access. Economic downturns could reduce demand for cosmetic procedures, affecting revenue. Product liability claims and recalls pose a threat to the company's reputation and financial performance. Dependence on key personnel and the ability to attract and retain talent are also critical risks.

Industry Context

InMode operates within the rapidly growing aesthetic medical device industry. The market is driven by increasing demand for minimally invasive cosmetic procedures and technological advancements. The competitive landscape includes companies offering various energy-based devices and surgical solutions. InMode differentiates itself through its proprietary radiofrequency technologies and a comprehensive product portfolio. The global medical aesthetics market is projected to reach billions of dollars in the coming years, fueled by an aging population and rising disposable incomes. InMode is well-positioned to capitalize on these trends with its innovative products and established market presence.

Key Customers

  • Physicians specializing in dermatology and plastic surgery.
  • Medical spas and aesthetic clinics.
  • Hospitals and healthcare facilities offering cosmetic procedures.
  • Women seeking solutions for health conditions.
AI Confidence: 73% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q4 2025 $104M $27M $0.42
Q3 2025 $93M $22M $0.34
Q2 2025 $96M $27M $0.42
Q1 2025 $78M $18M $0.26

Source: Company filings

Chart & Info

Price Chart

InMode Ltd. (INMD) stock price: $15.19 (+0.39, +2.64%)

Why Bull

  • InMode's consistent stream of new product launches keeps them fresh and competitive, signaling innovation and growth potential.
  • Recent insider buying activity often reflects management's confidence in the company's future prospects and stock valuation.
  • The overall positive community sentiment suggests a strong belief in InMode's long-term strategy and market position.
  • InMode's focus on minimally invasive cosmetic procedures aligns well with current consumer preferences, potentially driving demand.

Why Bear

  • Increased competition in the aesthetic device market could erode InMode's market share and pricing power.
  • Negative community discussions around potential regulatory changes might create uncertainty about future profitability.
  • Recent reports of slower sales growth in certain regions could signal a weakening demand for InMode's products.
  • A shift in market perception due to emerging alternative technologies could negatively impact InMode's long-term outlook.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
729,219

Rationale

AI-generated technical analysis for INMD including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss InMode Ltd. (INMD) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for INMD.

Make a Prediction

Set your price target for InMode Ltd. (INMD), choose a timeframe, and track your prediction accuracy.

Current price: $15.19

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INMD.

Price Targets

Wall Street price target analysis for INMD.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

44.5/100

Score Factors

  • Revenue Growth 2/100
  • Gross Margin 10/100
  • Operating Leverage 4/100
  • Cash Runway 5/100
  • R&D Intensity 5/100
  • Insider Activity 6/100
  • Short Interest 5/100
  • Price Momentum 0/100
  • News Sentiment 5/100

What does this score mean?

The MoonshotScore rates INMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Medical - Devices

Competitors & Peers

Latest News

Frequently Asked Questions

What does InMode Ltd. do?

InMode Ltd. is a global medical device company that designs, develops, manufactures, and markets minimally invasive aesthetic medical products. The company's core technology is based on radiofrequency assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency (SDFR). These technologies are used in a variety of aesthetic procedures, including body contouring, skin tightening, and ablative skin rejuvenation. InMode sells its products to physicians, medical spas, and aesthetic clinics worldwide, offering a comprehensive portfolio of solutions for the aesthetic market.

Is INMD stock a good buy?

INMD stock presents a mixed picture. Its high profit margin of 41.0% and gross margin of 78.8% suggest strong profitability. The P/E ratio of 6.38 may indicate undervaluation. However, the high beta of 2.17 suggests significant volatility. Growth opportunities in new markets and applications exist, but competition and economic factors pose risks. Investors should weigh the potential for high returns against the increased risk before investing, considering their own risk tolerance and investment horizon.

What are the main risks for INMD?

The main risks for InMode include intense competition in the aesthetic medical device market, which could pressure pricing and market share. Changes in regulatory requirements and healthcare policies could impact product approvals and market access. Economic downturns could reduce demand for cosmetic procedures, affecting revenue. Product liability claims and recalls pose a threat to the company's reputation and financial performance. Dependence on key personnel and the ability to attract and retain talent are also critical risks.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.